Manajemen Hipertensi dengan Nifedipine GITS

Oleh :

dr. Audiza Luthffia

Nifedipine GITS atau Gastro Intestinal Therapeutic System merupakan antihipertensi golongan calcium-channel blocker (CCB) dihidropiridin yang sering digunakan sebagai manajemen hipertensi.

Hipertensi merupakan salah satu masalah kesehatan dunia karena prevalensinya yang tinggi dan merupakan faktor risiko berbagai penyakit, yang dapat menimbulkan komplikasi termasuk kematian. Pengendalian hipertensi adalah kunci untuk mencegah morbiditas dan mortalitas akibat penyakit kardiovaskular, serebrovaskular, serta kerusakan ginjal.

Dari seluruh golongan antihipertensi yang tersedia, obat penghambat sistem renin angiotensin dan penyekat kanal kalsium atau calcium channel blocker (CCB) merupakan dua golongan yang terbukti paling efektif untuk mencapai target tekanan darah yang direkomendasikan sekaligus memiliki profil toleransi yang baik. Golongan CCB merupakan salah satu obat antihipertensi yang paling banyak digunakan dalam 20 tahun terakhir. Selain karena efektif dan aman, banyak bukti ilmiah juga menyebutkan bahwa CCB dapat mencegah komplikasi kardiovaskular dan renal akibat hipertensi.[1-3]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Tocci G, Battistoni A, Passerini J, et al. Calcium Channel Blockers and Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics. 2015; 20(2); 121–130. Doi: 10.1177/1074248414555403
2. Volpe M. Calcium Channel Blockers for the Clinical Management of Hypertension. High Blood Press Cardiovasc Prev. 2018; 25: 1–3. Doi: 10.1007/s40292-017-0233-0 3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden disease. Lancet. 2002; 360(9343):1347-1360. 4. McKeever RG, Hamilton RJ. Calcium Channel Blockers. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482473/
5. Tung YC, Hsu TJ, Lin CP, et al. Efficacy and safety outcomes of one generic nifedipine versus ADALAT long-acting nifedipine for hypertension management. J Clin Hypertens (Greenwich). 2020; 22(12):2296-2305. doi: 10.1111/jch.14070.
6. Kandarini Y. Cardiovascular and Renal Protection Effect Of Nifedipine GITS in Hypertension. PKB ILMU PENYAKIT DALAM XXIV. 2016
7. Shimamoto K, Kimoto M, Matsuda Y, Asano K, Kajikawa M. Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. Hypertens Res. 2015;38(10):695-700. doi: 10.1038/hr.2015.54. 8. Adalat Oros Product Information. Available from: https://resources.bayer.com.au/resources/uploads/PI/file9304.pdf
9. Ueng KC, Ningling S, El Maksod A, et al. Efficacy and tolerability of long-acting nifedipine GITS/OROS monotherapy or combination therapy in hypertensive patients: results of a 12- week international, prospective, multicentre, observational study. Clin Drug Investig. 2011;31(9):631-42. doi: 10.2165/11588970-000000000-00000.
10. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005 Mar;23(3):641-8. doi: 10.1097/01.hjh.0000160223.94220.29. PMID: 15716708.
11. Snider ME, Nuzum DS, Veverka A. Long-acting nifedipine in the management of the hypertensive patient. Vasc Health Risk Manag. 2008;4(6):1249-57. doi: 10.2147/vhrm.s3661. 12. Botero R, Aroca G, Asa G, et al. Efficacy and safety of two different formulations of nifedipine (GITS) vs. slow release microgranules in patients with mild and moderate hypertension. J Hum Hypertens. 2002 Mar;16 Suppl 1:S156-60. doi: 10.1038/sj.jhh.1001364. PMID: 11986916.
13. Saito I, Saruta T; ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res. 2006;29(10):789-96. doi: 10.1291/hypres.29.789.
14. MJ Brown, CR Palmer, A Castaigne, PW de Leeuw, et al. Principal results from the international nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT), European Heart Journal Supplements. 2001; 3: 20-26. Doi: 10.1016/S1520- 765X(01)90053-7
15. Konoshita T, Makino Y, Kimura T, et al. Genomic Disease Outcome Consortium (G-DOC) Study Investigators. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers. Int J Cardiol. 2013; 20;166(2):448-52. doi: 10.1016/j.ijcard.2011.10.133
16. Pusat Informasi Obat Nasional. Badan Pengawas Obat dan Makanan. Nifedipin. Available from: http://pionas.pom.go.id/monografi/nifedipin
17. Rahimah SB. Kronoterapi pada penderita hipertensi. Bandung Meeting on Global Medicine & Health. 2018; 2: 14-20.
18. Chen L, Yang G. Recent advances in circadian rhythms in cardiovascular system. Front Pharmacol. 2015; 6:71. Published 2015 Apr 1. doi:10.3389/fphar.2015.00071 19. Hermida RC, Ayala DE, Mojón A, Fernández JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens. 2008;21(8):948-954. doi:10.1038/ajh.2008.216